View this email online

image HHT new scientific publication

We are proud to report that a new publication by our HHT-WG Chair Prof Claire Shovlin, the British Thoracic Society Clinical Statement on Pulmonary Arteriovenous Malformations, is now available. Pulmonary…

image The ERN Clinical Patient Management System (CPMS) is officially launched!

The much anticipated Clinical Patient Management System (CPMS) was released by the European Commission (DG SANTE) on Monday, November 20th, 2017 at 12:00 CET! This secure web-based application will be…

image Rare Disease UK Survey

Rare disease UK has created a survey for rare disease patients and their families. The goal is to gather valuable information about the emotional impact of living with a rare disease…

image HHT ePAG Meeting

During the HHT Europe annual meeting, which took place in Hamburg this month, the HHT patient organisations members of our VASCERN ePAG for HHT had a face-to-face meeting. The ePAG…

image European Medicines Agency (EMA) in Amsterdam

It was announced on November 20th, 2017 that the European Medicines Agency (EMA) will relocate to Amsterdam. This agency plays a crucial role in the development and authorization of orphan…

image Parliamentary Advocates for Rare Diseases

Eurordis has launched the network of Parliamentary Advocates for Rare Diseases. This network of European and national Members of Parliament will advocate in the goal of improving the lives of…

image VASCERNdays2017: Success of our First Annual Seminar!

More than 80 participants gathered during the VASCERN days 2017, our 1st 2 days Annual Seminar, which took place in Paris on October 13 & 14, 2017. A big thank you…

image VASCERN is now on Facebook!

The VASCERN coordination team is very happy to announce that we now have an official Facebook page! As planned in our 1st year Action Plan (WP 10 on Communication), this Facebook page will…

image VASCERN YouTube Channel is launched

The  availability of conferences on YouTube via the VASCERN YouTube Channel is part of our first year action plan (Work Package 7). Our objective is to share content about: VASCERN…


Up-coming events


EU calls

  • Thu
    07
    Dec
    2017

    Publication of the call of December 7th!

    JTC 2018: "Transnational research projects on hypothesis-driven use of multi-omic integrated approaches for discovery of disease causes and/or functional validation in the context of rare diseases"

    More information here

  • Tue
    09
    Jan
    2018
    5 PM (GMT +1)

    The ERN Call for Specific Grant Agreement (SGA) for the 2nd year of ERN operation (March 2018-February 2019), under the ERN 5 years Framework Partnership Agreement, has been launched on November, 22nd. The deadline to answer is on January, 9th, 2018.

    VASCERN has signed a 5 years Framework Partnership Agreement (FPA) with the European Commission (2017-2022), therefore is eligible for this European Union funding for ERNs, and was invited to answer this call for a second year SGA.

    We are currently working on our proposal for our 2nd year Action Plan and budget to answer this call.

    Support for ERNs Coordination & Operation is provided by the European Union 3rd Health Programme.

    The European Union is co-funding 60% of the total budget. The maximum amount of EU contribution is 200 000 euros by ERN.

    More information 

    Database of EU 3rd Health Programme co-funded projects

    Database: info on VASCERN Framework Partnership Agreement 

    Database: info on VASCERN Specific Grant Agreement (March 2017-February 2018)

     

  • Wed
    18
    Apr
    2018

    The European Commision Call for the European Joint Programme Co-fund on Rare Diseases has been published:

    http://ec.europa.eu/research/participants/portal/desktop/en/opportunities/h2020/topics/sc1-bhc-04-2018.html

    The overall objective is to implement a European Joint Programme (EJP) Cofund for Rare Diseases which would create a research and innovation pipeline "from bench to bedside" ensuring rapid translation of research results into clinical applications and uptake in healthcare for the benefit of patients.

    The initiative should follow the policies and contribute to the objctives of the International Rare Diseases Research Consortium (IRDiRC).